Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;13(2):41-5.
doi: 10.5049/EBP.2015.13.2.41. Epub 2015 Dec 30.

Hypertension in Chronic Glomerulonephritis

Affiliations
Review

Hypertension in Chronic Glomerulonephritis

Chun-Gyoo Ihm. Electrolyte Blood Press. 2015 Dec.

Abstract

Chronic glomerulonephritis (GN), which includes focal segmental glomerulosclerosis and proliferative forms of GN such as IgA nephropathy, increases the risk of hypertension. Hypertension in chronic GN is primarily volume dependent, and this increase in blood volume is not related to the deterioration of renal function. Patients with chronic GN become salt sensitive as renal damage including arteriolosclerosis progresses and the consequent renal ischemia causes the stimulation of the intrarenal renin-angiotensin-aldosterone system(RAAS). Overactivity of the sympathetic nervous system also contributes to hypertension in chronic GN. According to the KDIGO guideline, the available evidence indicates that the target BP should be ≤140mmHg systolic and ≤90mmHg diastolic in chronic kidney disease patients without albuminuria. In most patients with an albumin excretion rate of ≥30mg/24 h (i.e., those with both micro-and macroalbuminuria), a lower target of ≤130mmHg systolic and ≤80mmHg diastolic is suggested. The use of agents that block the RAAS system is recommended or suggested in all patients with an albumin excretion rate of ≥30mg/ 24 h. The combination of a RAAS blockade with a calcium channel blocker and a diuretic may be effective in attaining the target BP, and in reducing the amount of urinary protein excretion in patients with chronic GN.

Keywords: Chronic glomerulonephritis; RAAS blockade; Volume dependent.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nachman PH, Jennette JC, Falk RJ. Primary glomerular disease. In: Brenner BM, Rector FC Jr, editors. The kidney. 10th ed. Philadelphia: Saunders; 2011. pp. 1101–1191.
    1. Orofino L, Quereda C, Lamas S, Orte L, Gonzalo A, Mampaso F, et al. Hypertension in primary chronic glomerulonephritis: analysis of 288 biopsied patients. Nephron. 1987;45:22–26. - PubMed
    1. Csiky B, Kovács T, Wágner L, Vass T, Nagy J. Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Nephrol Dial Transplant. 1999;14:86–90. - PubMed
    1. Kaplan NM. Clinical Hypertension. 7th ed. Baltimore: Williams & Wilkins; 1998. Renal parenchymal hypertension; pp. 281–299.
    1. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699–706. - PubMed

LinkOut - more resources